We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Susceptibility Loci for Colorectal Cancer Identified by Genome-Wide Association Studies on East Asians

By LabMedica International staff writers
Posted on 07 Jan 2013
A genome-wide association study (GWAS) conducted on individuals from several East Asian countries identified four genetic foci linked to colorectal cancer, three of which were also found in a population of European descent.

A GWAS is an examination of many common genetic variants in different individuals to see if any variant is associated with a trait. More...
A GWAS typically focuses on associations between single-nucleotide polymorphisms (SNPs) and traits such as major diseases. These studies normally compare the DNA of two groups of participants: people with the disease (cases) and similar people without (controls). Each person gives a sample of DNA, from which millions of genetic variants are read using SNP arrays. If one type of the variant is more frequent in people with the disease, the SNP is said to be "associated" with the disease. The associated SNPs are then considered to mark a region of the human genome, which influences the risk of disease. In contrast to methods that specifically test one or a few genetic regions, a GWAS investigates the entire genome. A GWAS identifies SNPs and other variants in DNA, which are associated with a disease, but cannot on its own specify which genes cause the illness.

In a paper published in the December 23, 2012, online edition of the journal Nature Genetics investigators at Vanderbilt University (Nashville, TN, USA) searched for new genetic factors associated with colorectal cancer (CRC) by conducting a GWAS on an East Asian test group comprising 2,098 cases and 5,749 controls. From this group they selected 64 promising SNPs for replication in an independent set of samples, including up to 5,358 cases and 5,922 controls. Results of the second study yielded four foci linked to CRC. Three of the four were replicated in a study conducted in 26,060 individuals of European descent.

"Looking at different ethnic groups is important because the genetic structures can be different enough that variants identified in one population do not explain risk in other populations," said senior author Dr. Wei Zheng, professor of cancer research at Vanderbilt University. "Because of the difference in genetic structures and underlying environment exposures, it might be easier to discover some risk variants in studies conducted in non-European populations."

"The findings from this study are relevant to both Asian and European populations," said Dr. Zheng. "Interestingly, these three susceptibility loci were not discovered in previous studies conducted in European-ancestry populations. These new discoveries are very exciting. They will certainly lead to future studies regarding the biology of these regions and the translational potential of these findings in cancer prevention and treatment."

Related Links:
Vanderbilt University


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.